These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35136963)

  • 1. Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis.
    Oba A; Wu YHA; Colborn KL; Karam SD; Meguid C; Al-Musawi MH; Bao QR; Gleisner AL; Ahrendt S; Schulick RD; Del Chiaro M
    Br J Surg; 2022 Apr; 109(5):450-454. PubMed ID: 35136963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
    Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
    Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
    Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
    World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adenocarcinoma.
    Suto H; Oshima M; Ando Y; Matsukawa H; Takahashi S; Shibata T; Kamada H; Kobara H; Masaki T; Kumamoto K; Suzuki Y; Okano K
    HPB (Oxford); 2023 Jan; 25(1):136-145. PubMed ID: 36307256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
    Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
    Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy.
    Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
    Ann Surg Oncol; 2023 Apr; 30(4):2458-2468. PubMed ID: 36575288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Lin H; Wang L; Zhong X; Zhang X; Shao L; Wu J
    World J Surg Oncol; 2021 May; 19(1):141. PubMed ID: 33952287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study.
    Suto H; Matsukawa H; Fuke T; Nagao M; Ando Y; Oshima M; Yamana H; Kamada H; Kobara H; Okuyama H; Kumamoto K; Okano K
    Pancreatology; 2024 May; 24(3):431-436. PubMed ID: 38383175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Nishiwada S; Sho M; Cui Y; Yamamura K; Akahori T; Nakagawa K; Nagai M; Nakamura K; Takagi T; Ikeda N; Li W; Baba H; Goel A
    Int J Cancer; 2021 Feb; 148(3):769-779. PubMed ID: 32895958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.
    Oshima M; Okano K; Suto H; Ando Y; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
    BMC Gastroenterol; 2020 Dec; 20(1):423. PubMed ID: 33317455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma.
    Matsumura M; Honda G; Tani K; Nemoto S; Ome Y; Hayakawa S; Suzuki M; Horiguchi SI; Kikuyama M; Seyama Y
    Ann Gastroenterol Surg; 2023 Mar; 7(2):306-317. PubMed ID: 36998294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
    Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
    World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Terai T; Nishiwada S; Nagai M; Nakamura K; Kohara Y; Yasuda S; Matsuo Y; Doi S; Sakata T; Kumada H; Watanabe M; Sho M
    Pancreatology; 2024 Sep; 24(6):938-946. PubMed ID: 39152081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from A Japanese Nationwide Study.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Takeuchi H; Muto M; Kakeji Y; Kitagawa Y; Doki Y
    Ann Surg Oncol; 2023 Sep; 30(9):5885-5894. PubMed ID: 37264286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy.
    Sugawara T; Rodriguez Franco S; Sherman S; Kirsch MJ; Colborn K; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
    JAMA Oncol; 2023 Mar; 9(3):316-323. PubMed ID: 36480190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.
    Kubota K; Sato T; Watanabe S; Hosono K; Kobayashi N; Mori R; Taniguchi K; Matsuyama R; Endo I; Nakajima A
    Dig Endosc; 2014 Jan; 26(1):77-86. PubMed ID: 23551230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival after neoadjuvant approaches to gastroesophageal junction cancer.
    Xiang M; Chang DT; Heestand GM; Pollom EL
    Gastric Cancer; 2020 Jan; 23(1):175-183. PubMed ID: 31230228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.